business info

  • Musculoskeletal
  • Gastrointestinal (GI)
  • Cardiovascular (CV)
  • Urology
  • Antibiotics
  • Blood Preparetions
  • Vaccines
  • Parenteral Nutritions
  • Other Rx
HOME › Product info › Oncology

Oncology

sunpla sunpla
  • The First New Drug Developed in Korea
  • Third Generation of Platinum Complex Anti-cancer Agents with high efficacy and fewer adverse reactions
  • descriptin
    Sunpla (Heptaplatin) is a new anti-cancer agent, the third generation of platinum complexes after Cisplatin and Carboplatin. Sunpla acquired final permission from KFDA (Korea Food & Drug Administration) as the first domestically developed new drug on July 14, 1999 after 9 years of R&D from May 1990.
    Clinical studies conducted on Supla demonstrate its ability to treat cancer, especially gastric cancer, the most common type of cancer in Korea. The results of the studies show that its effectiveness in treating cancer matches or exceeds that of existing chemotherapies, with fewer adverse reactions.
  • indication &usage
    Heptaplatin --------------- 50mg or 100mg / 1 vial
  • dosage &administration
    Treatment of progressive, metastatic or post-operative relapsing gastric cancer combined with 5-fluorouracil.
  • characteristics
    1. 1. Sunpla (Heptaplatin) is the third generation of platinum complex anti-cancer agents after Cisplatin and Carboplatin.

    2. 2. Its effectiveness in treating cancer matches or exceeds that of existing chemotherapies, especially with regard to gastric cancer.

    3. 3. Supla is a safe anti-cancer agent with mild & low adverse reactions. Alopecia and neurotoxicity, two of the most serious adverse reactions in chemotherapy were less than degree 2 in Sunpla treatment. In addition, vomiting occurred in only 3.3% of patients, which is much less compared with the 36.5% of existing chemotherapies.

list